Synapse

← Blood Cancer Discovery

Papers in Blood Cancer Discovery

Page 1 · newest first

  1. Preclinical characterization of the potent and selective MALT1 inhibitor safimaltib in B-cell lymphoma modelsBlood Cancer Discovery · 2026
  2. Targeting MALT1 in B-cell LymphomasBlood Cancer Discovery · 2026
  3. Key Challenges on the Path toward Precision Immunotherapy for Large B-cell LymphomaBlood Cancer Discovery · 2026
  4. Prophylactic IFN-γ blockade drives axi-cel expansion without preventing refractory toxicities: caution against pre-emptive useBlood Cancer Discovery · 2026
  5. CD19 CAR T-cell Escape in Large B-cell Lymphoma: Antigen Density Matters after AllBlood Cancer Discovery · 2026
  6. A (Post)translational Opportunity in RAS-Dependent Heme MalignancyBlood Cancer Discovery · 2026
  7. A phase 1, first-in-human study of safimaltib, a MALT1 inhibitor, in B-lymphocytic malignanciesBlood Cancer Discovery · 2026
  8. Very Long Chain Fatty Acid Synthesis is a Targetable Dependency in RAS Pathway Mutant LeukemiaBlood Cancer Discovery · 2026
  9. In vivo CAR T-cell therapy: determinants of response and durabilityBlood Cancer Discovery · 2026
  10. Germline noncoding risk variants influence clonal hematopoiesis through altered hematopoietic enhancer activityBlood Cancer Discovery · 2026
  11. Therapy-persistent leukemia is selectively vulnerable to SLC23A1 restoration via targeting KHSRPBlood Cancer Discovery · 2026
  12. Spatial profiling identifies a distinct and topographically-defined tumor microenvironment that emerges during multiple myeloma evolutionBlood Cancer Discovery · 2026
  13. Tumor CD19 Expression Determines Distinct Clinical Outcomes After CD19 CAR T-Cell Therapy in Large B-Cell LymphomaBlood Cancer Discovery · 2026
  14. CAR T Cells Targeting an Intracellular Leukemia Antigen Promiscuously Presented by Diverse HLA-II AllelesBlood Cancer Discovery · 2026
  15. Sequenced, Not Stirred: Positioning CAR T and Bispecific Antibody Therapy in Multiple MyelomaBlood Cancer Discovery · 2026
  16. Hattrick against Lymphoma with Trispecific CAR T CellsBlood Cancer Discovery · 2026
  17. A Living Archive of High-risk LymphomaBlood Cancer Discovery · 2026
  18. Personalized Circulating Tumor DNA Profiling Enables Superior and Universal Residual Disease Detection in Acute Myeloid LeukemiaBlood Cancer Discovery · 2026
  19. Predictive Models for Toxicities after CAR T-cell Therapy: Challenges and OpportunitiesBlood Cancer Discovery · 2026
  20. Glofitamab-Based Therapy for Relapsed or Refractory CNS Lymphoma: A Multicenter Retrospective StudyBlood Cancer Discovery · 2026
  21. LY3410738, a Covalent Inhibitor of Mutant IDH1/2, is Effective in Acute Myeloid Leukemia Preclinical ModelsBlood Cancer Discovery · 2026
  22. The Nicotinamide Salvage Pathway is a Metabolic Vulnerability of High-Risk MDS Stem CellsBlood Cancer Discovery · 2026
  23. Safety and clinical outcomes of a first-in-human trial of point-of-care manufactured trispecific CAR T cells targeting CD19, CD20, and CD22Blood Cancer Discovery · 2026
  24. Genetic Mutation and Epigenetic Silencing Drive Antigen-Negative Relapse in CD7 CAR-T Treated T-cell Lymphoid MalignanciesBlood Cancer Discovery · 2026
  25. BTK Degraders in Lymphoid Malignancies: New Modality, New Resistance Rules?Blood Cancer Discovery · 2026
  26. Abstract A015: Immunoglobulinheavy chain variable region gene mutational status in chronic lymphocytic leukemia patients in NigeriaBlood Cancer Discovery · 2026
  27. Abstract A009: PKCδ-mediated feedback control of B-cell receptor signaling and its subversion in diffuse large B-cell lymphomaBlood Cancer Discovery · 2026
  28. Abstract A003: CD74 as a novel chimeric antigen receptor (CAR)-T cell target for cHL and the TMEBlood Cancer Discovery · 2026
  29. Abstract A013: Impact of putative cell of origin on CD19+CAR-T outcomes in patients with large B-cell lymphomaBlood Cancer Discovery · 2026
  30. Abstract A043: Reduced KLF2 expression in canine marginal zone lymphoma mirrors human diseaseBlood Cancer Discovery · 2026
  31. Abstract A047: Final analysis of a Phase 1 study of ibrutinib dose-escalation in TEDDI-R with isavuconazole for relapsed or refractory primary DLBCL of the CNSBlood Cancer Discovery · 2026
  32. Abstract A058: Clinical and preclinical evidence indicate gender-based differences in the sensitivity of B-cell lymphoid tumors to BTK inhibitorsBlood Cancer Discovery · 2026
  33. Abstract IA003: Multitargeted combination strategies to cure patients with Large B-cell LymphomaBlood Cancer Discovery · 2026
  34. Abstract A054: Commensal bacteria drive B-cell lymphoma development and progression in the presence of intact innate immunityBlood Cancer Discovery · 2026
  35. Abstract A028: Targeting eIF4A1 reveals crosstalk between BCR signaling and translation in aggressive B-cell lymphomaBlood Cancer Discovery · 2026
  36. Abstract A031: Splicing-derived neoantigens in DLBCL reveal subtype- and cell-type-specific predicted neoantigen targetsBlood Cancer Discovery · 2026
  37. Abstract A026: Uncovering the biological contribution of polatuzumab vedotin when combined with glofitamab in R/R large B-cell lymphomaBlood Cancer Discovery · 2026
  38. Abstract A036: Amplifying B-cell lymphoma apoptosis by targeting two oncoproteins with a new bispecific compoundBlood Cancer Discovery · 2026
  39. Abstract PR001: Cytokine-linked stromal remodeling in transformed follicular lymphoma impacts macrophage function and can be detected non-invasivelyBlood Cancer Discovery · 2026
  40. Abstract A030: Striking Gold: CpG gold (Au) lipid nanoparticles (CAL) promote toll-like receptor 9 mediated killing in mouse and human lymphomasBlood Cancer Discovery · 2026
  41. Abstract IA008: Epigenetic regulation of the lymphoma microenvironment: from single-cell behavioral reprogramming to systems-level niche corruptionBlood Cancer Discovery · 2026
  42. Abstract A007: Patterns of DNA methylation in HIV-associated DLBCLBlood Cancer Discovery · 2026
  43. Abstract PR007: Mechanisms and impact of bystander killing by CAR T cellsBlood Cancer Discovery · 2026
  44. Abstract PR003: BTG1 mutation induces an age-associated B cell precursor population with extranodal and brain-infiltrating potential in diffuse large B cell lymphoma via interleukin-21 hypersensitivityBlood Cancer Discovery · 2026
  45. Abstract PR004: BTK A428D is a recurrent pan-resistance mutation to BTK degraders in clinical trialsBlood Cancer Discovery · 2026
  46. Abstract A041: Prognostic significance of post-CAR-T macrocytosis in large B-cell lymphomaBlood Cancer Discovery · 2026
  47. Abstract A024: Harnessing repressive β-catenin-LEF1 complexes in chronic lymphocytic leukemia and Richter’s transformationBlood Cancer Discovery · 2026
  48. Abstract A033: Inhibitors of GRK2-targeting-microRNAs: New therapeutic strategies for MALT1-dependent lymphomasBlood Cancer Discovery · 2026
  49. Abstract A022: A naturally occurring feline model for human indolent intestinal T-cell neoplasiaBlood Cancer Discovery · 2026
  50. Abstract IA011: Ccnd1 initiates mantle cell lymphoma–like disease and cooperates with Sox11 expression and loss of Atm/Trp53 in autochthonous mouse modelsBlood Cancer Discovery · 2026